Adeza (NASDAQ:ADZA) today announced financial results for the
second quarter ended June 30, 2006. Adeza reported record product
sales of $13.0 million for the second quarter of 2006, an increase
of 23% from product sales of $10.6 million for the second quarter
of 2005. This increase was due to higher sales volume of
FullTerm(TM), The Fetal Fibronectin Test. Net income for the second
quarter of 2006 was $537,000, or diluted earnings per share of
$0.03, which included charges of $931,000 for stock-based
compensation expense. Net income for the second quarter of 2005 was
$1.8 million, or diluted earnings per share of $0.10, which
included no stock-based compensation expense related to SFAS 123R
and a 5% tax rate. Gross profit for the second quarter of 2006 was
$11.1 million, or 85.4%, and included stock-based compensation
expense of $48,000. This compares with gross profit of $9.2
million, or 86.6%, for the second quarter of 2005. Sales and
marketing expenses for the second quarter of 2006 were $7.4
million, including stock-based compensation expense of $457,000,
compared with $4.8 million for the same quarter in 2005. This
increase reflects expansion of the company's direct sales force and
marketing programs. General and administrative expenses for the
second quarter of 2006 were $2.2 million, including stock-based
compensation expense of $352,000, compared with $1.9 million in the
comparable quarter of the prior year. Research and development
expenses were $1.6 million for the second quarter of 2006,
including stock-based compensation expense of $75,000, compared
with $1.2 million in the same quarter of the prior year. This
increase was mainly due to product development efforts, including
costs related to Gestiva(TM), Adeza's drug candidate for the
prevention of preterm birth in women with a history of preterm
delivery. Product sales for the first half of 2006 totaled $23.8
million, an increase of 18% from $20.2 million for the first half
of 2005. For the six months ended June 30, 2006 Adeza reported net
income of $543,000, or diluted earnings per share of $0.03, which
included $1.8 million for stock-based compensation expense due to
the adoption of SFAS 123R. This compares with net income of $3.3
million, or diluted earnings per share of $0.18, for the six months
ended June 30, 2005, which included no employee stock-based
compensation expense related to SFAS 123R and a 5% tax rate. As of
June 30, 2006 Adeza had cash and cash equivalents of $93.4 million,
an increase of $2.8 million from $90.5 million of cash and cash
equivalents as of March 31, 2006 and an increase of $3.6 million
since December 31, 2005. Stockholders' equity was $100.2 million
and working capital was $99.5 million as of June 30, 2006. "We see
significant opportunity for growth in the 'signs-and-symptoms'
market, while continuing marketing programs aimed at expanding
FullTerm, The Fetal Fibronectin Test to women who are at risk for
preterm birth," said Emory V. Anderson, president and chief
executive officer. "We are pleased with the regulatory progress of
Gestiva, our drug candidate for the prevention of preterm birth in
women with a history of preterm delivery," he continued. "Since
announcing the submission of the Gestiva New Drug Application (NDA)
in early May, the U.S. Food and Drug Administration (FDA) has
accepted the NDA filing and assigned a date of August 29 for an
advisory committee meeting. The FDA has also granted the NDA
Priority Review designation, setting a goal to complete its review
or otherwise respond to the Gestiva NDA by October 20. If approved,
Gestiva will have a favorable impact on our 2007 product sales."
2006 Financial Guidance Adeza today affirmed guidance for 2006
revenue to be in the range of $54 million to $57 million. It also
affirmed that gross margin for 2006 is expected to exceed 80%, and
has revised the full-year tax rate to a range of 48% to 52%, which
is higher than the statutory tax rate primarily as a result of
accounting for stock-based compensation expense under SFAS 123R.
Conference Call Adeza's management will host an
investment-community conference call today beginning at 4:30 p.m.
Eastern time (1:30 p.m. Pacific time) to discuss these results and
to answer questions. Individuals interested in participating in the
conference call may do so by dialing (888) 463-4383 for domestic
callers, or (706) 634-5615 for international callers. A telephone
replay will be available for 48 hours following the conclusion of
the call by dialing (800) 642-1687 for domestic callers, or (706)
645-9291 for international callers, and entering reservation code
3584280. The live call also will be available via the Internet on
the Investor Relations section of the company's Web site at
www.adeza.com. A webcast replay of the call will be available
following the conclusion of the call. About Adeza Adeza designs,
manufactures and markets innovative products for women's health.
Adeza's initial focus is on reproductive healthcare using its
proprietary technologies to predict preterm birth and assess
infertility. Adeza's principal product is a patented diagnostic
test, FullTerm, The Fetal Fibronectin Test, which utilizes a
single-use, disposable cassette and is analyzed on Adeza's patented
TLiIQ(R) System. This product is approved by the U.S. Food and Drug
Administration (FDA) for use in assessing the risk of preterm
birth. Adeza also markets and sells the E-tegrity(R) Test, an
infertility-related test to assess receptivity of the uterus to
embryo implantation in women with unexplained infertility. In May
2006, Adeza announced the submission of its New Drug Application
(NDA) to the FDA for Gestiva, a long-acting form of a naturally
occurring progesterone to prevent preterm birth in women with a
history of preterm delivery. Adeza's NDA submission includes data
from a clinical study conducted by the National Institutes of
Health. In June 2006, the NDA for Gestiva was granted Priority
Review status. More information is available at www.adeza.com.
Adeza cautions you that statements included in this press release
that are not a description of historical facts are forward-looking
statements, including for example, projections about Adeza's
anticipated expenses and financial performance and statements
related to Gestiva's regulatory status and medical potential. The
inclusion of forward-looking statements should not be regarded as a
representation by Adeza that any of its plans will be achieved.
Actual results may differ materially from those set forth in this
release due to the risks and uncertainties inherent in Adeza's
business including, without limitation, risks related to the
anticipated regulatory or commercial path for its product
candidates. Further information about these and other risks is
included Adeza's Annual Report on Form 10-K and other periodic and
current reports filed by Adeza with the Securities Exchange
Commission, which are available from the SEC's Web site
(www.sec.gov), and also available on the Investor Relations section
of Adeza's Web site. All forward-looking statements are qualified
in their entirety by this cautionary statement and Adeza undertakes
no obligation to revise or update this news release to reflect
events or circumstances after the date hereof. -0- *T ADEZA
BIOMEDICAL CORPORATION CONDENSED STATEMENTS OF INCOME (In
thousands, except per share amounts) (Unaudited) Three Months Ended
Six Months Ended June 30, June 30, --------------------
----------------- 2006 2005 2006 2005 -------- -------- --------
-------- Product sales $ 13,029 $ 10,634 $23,822 $20,244 Cost of
product sales 1,907 1,429 3,662 2,856 -------- -------- --------
-------- Gross profit 11,122 9,205 20,160 17,388 Operating costs
and expenses: Sales and marketing 7,416 4,787 13,461 9,512 General
and administrative 2,160 1,867 4,462 3,404 Research and development
1,600 1,213 3,273 2,077 -------- -------- -------- -------- Total
operating costs and expenses 11,176 7,867 21,196 14,993 Income
(loss) from operations (54) 1,338 (1,036) 2,395 Interest income
1,128 593 2,122 1,073 -------- -------- -------- -------- Income
before provision for income taxes 1,074 1,931 1,086 3,468 Provision
for income taxes 537 102 543 183 -------- -------- --------
-------- Net income $ 537 $ 1,829 $ 543 $ 3,285 ======== ========
======== ======== Net income per share: Basic $ 0.03 $ 0.11 $ 0.03
$ 0.20 ======== ======== ======== ======== Diluted $ 0.03 $ 0.10 $
0.03 $ 0.18 ======== ======== ======== ======== Shares used to
compute net income per share: Basic 17,467 16,755 17,442 16,707
======== ======== ======== ======== Diluted 18,128 17,697 18,187
17,762 ======== ======== ======== ======== ADEZA BIOMEDICAL
CORPORATION CONDENSED BALANCE SHEETS (In thousands, except par
value) June 30, Dec. 31, 2006 2005 ----------- ---------
(Unaudited) (1) ASSETS Current assets: Cash and cash equivalents
$93,357 $89,722 Accounts receivable, net 9,173 9,182 Inventories
965 849 Prepaid expenses and other current assets 504 292 Current
deferred tax asset 4,929 4,929 ----------- --------- Total current
assets 108,928 104,974 Property and equipment, net 419 348
Noncurrent deferred tax asset 193 193 Intangible assets, net 104
128 ----------- --------- Total assets $109,644 $105,643
=========== ========= LIABILITIES AND STOCKHOLDERS' EQUITY Current
liabilities: Accounts payable $2,287 $1,994 Accrued compensation
2,588 2,216 Accrued royalties 1,411 1,427 Other accrued liabilities
1,813 1,246 Taxes payable 1,284 1,322 Deferred revenue 32 33
----------- --------- Total current liabilities 9,415 8,238
Stockholders' equity: Common stock, $0.001 par value; 100,000
shares authorized; 17,482 and 17,376 shares issued and outstanding
at June 30, 2006 and December 31, 2005, respectively 17 17
Additional paid-in capital 132,096 132,432 Deferred compensation --
(2,604) Accumulated other comprehensive income 13 -- Accumulated
deficit (31,897) (32,440) ----------- --------- Total stockholders'
equity 100,229 97,405 ----------- --------- Total liabilities and
stockholders' equity $109,644 $105,643 =========== ========= (1)
Derived from the December 31, 2005 audited financial statements
included in the Annual Report on Form 10-K of Adeza Biomedical
Corporation for 2005. *T
Adeza (NASDAQ:ADZA)
๊ณผ๊ฑฐ ๋ฐ์ดํฐ ์ฃผ์ ์ฐจํธ
๋ถํฐ 5์(5) 2024 ์ผ๋ก 6์(6) 2024
Adeza (NASDAQ:ADZA)
๊ณผ๊ฑฐ ๋ฐ์ดํฐ ์ฃผ์ ์ฐจํธ
๋ถํฐ 6์(6) 2023 ์ผ๋ก 6์(6) 2024